Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparininduced thrombocytopenia

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 402-409

  Legnani, Cristina ^a   Cini, Michela ^a   Pili, Caterina ^a   Boggian, Ottavio ^a   Frascaro, Mirella ^a   Palareti, Gualtiero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diagnosis; Heparin induced thrombocytopenia; HIT; Immunoassay

Indexed keywords

HEPARIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; THROMBOCYTE FACTOR 4;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUTOMATION; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE DIAGNOSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTICOAGULANTS; AUTOMATION, LABORATORY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMILUMINESCENT MEASUREMENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPARIN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; ITALY; MALE; MIDDLE AGED; OBSERVER VARIATION; PILOT PROJECTS; PLATELET FACTOR 4; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 77955444577     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0002     Document Type: Article

References (33)

1. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update. Thromb Res 2006; 118: 165-176.
2. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21: 589-607.
3. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin- induced thrombocytopenia. Chest 2008; 133: 340S-380S.
4. Chong BH, Isaacs A. Heparin-induced thrombocytopenia: what clinicians need to know. Thromb Haemost 2009; 101: 279-283.
5. Nowak G. Heparin-induced thrombocytopenia (HIT II) - a drug-associated autoimmune disease. Thromb Haemost 2009; 102: 887-891.
6. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-3699.
7. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
8. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004; 104: 3072-3077.
9. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-555.
10. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127: 35S-45S.
11. Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006; 20: 259-272.
12. Greinacher A, Michels I, Kiefel V, et al. A Rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-736.
13. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4 heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381-385.
14. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the c-14-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648-654.
15. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-1246.
16. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-2536.
17. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin- induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373-1379.
18. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-350.
19. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
20. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. Br Med J 2004; 329: 168-169.
21. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005; 365: 1500-1505.
22. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 1666-1673.
23. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl 1): 9-12.
24. Amiral J, Wolf M, Fischer A, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-959.
25. Lindhoff-Last E, Gerdsen F, Ackermann H, et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 886-890.
26. Warkentin TE, Sheppard JAI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005; 146: 341-346.
27. Pouplard C, Leroux D, Regina S, et al. Effectiveness of a new immuno-assay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103: 145-150.
28. Alberio L, Kimmerle S, Baumann A, et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114: 528-536.
29. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133-2137.
30. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-1312.
31. Weiss BM, Shumway NM, Howard RS, et al. Optical density values correlate with the clinical probability of heparin induced thrombocytopenia. J Thromb Thrombolysis 2008; 26: 243-247.
32. Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies - distinguishing "signal" from "noise". Thromb Haemost 2008; 100: 523-524.
33. Bakchoul T, Giptner A, Najaoui A, et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1260-1265.